BI-1622
BI-1622 is an orally active, potent and highly selective HER2 (ERBB2) inhibitor, with an IC50 of 7 nM. BI-1622 shows greater than 25-fold selectivity over EGFR. BI-1622 shows high antitumor efficacy in vivo in xenograft mouse tumor models with engineered H2170 and PC9 cells and had a favorable agent metabolism and pharmacokinetics profile[1].
Product Specifications
CAS Number
2681392-19-6
UNSPSC
12352005
Target
Btk; CDK; EGFR; Itk; JAK; PI4K; Raf
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Epigenetics; JAK/STAT Signaling; MAPK/ERK Pathway; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/bi-1622.html
Purity
98.97
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(N1CCN(CC1)C2=NC3=C(NC4=CC=C(C(C)=C4)OC5=CC6=NC=NN6C=C5)N=CN=C3C=N2)C=C
Molecular Formula
C26H24N10O2
Molecular Weight
508.53
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CDK11; EGFR/ErbB1/HER1; ErbB2/HER2; ErbB4/HER4; JAK3
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Synaptogyrin 4 (SYNGR4) Human Gene Knockout Kit (CRISPR)
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2742), CF740 conjugate, 0.1mg/mL
